NUVB
Nuvation Bio Inc - Ordinary Shares - Class A

2,608
Loading...
Loading...
News
all
press releases
Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +93.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of +14.29% and +1.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy
Nuvation Bio (NUVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3mo ago
News Placeholder
Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief...
Business Wire·7mo ago
News Placeholder
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm PR Newswire NEW YORK, Feb. 18, 2025 NEW YORK, Feb. 18...
PR Newswire·8mo ago
News Placeholder
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access Program (EAP) for...
Business Wire·8mo ago
News Placeholder
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief...
Business Wire·9mo ago
News Placeholder
Nuvation Bio Receives Approval from Chinas National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that Chinas National Medical Products Administration (NMPA...
Business Wire·9mo ago
News Placeholder
Innovent Announces Second New Drug Application of DOVBLERON (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration
Innovent Announces Second New Drug Application of DOVBLERON (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration Innovent Announces Second...
PR Newswire·9mo ago

Latest NUVB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.